From: Effect of external use of Qingluo San on clinical efficacy in patients with acute gouty arthritis
Treatment group (n = 29) | Control group (n = 29) | p | |
---|---|---|---|
Age (years, mean ± standard deviation) | 54.66 ± 10.24 | 54.83 ± 11.79 | 0.953 |
Gender [n(%)] | |||
Male | 26 | 27 | 1.000 |
Female | 3 | 2 | |
History of gout (years, median [range]) | 3 (0–10) | 3 (0–11) | 0.856 |
BMI (kg/m2, mean ± standard deviation) | 26.70 ± 4.07 | 26.20 ± 5.00 | 0.678 |
Uric acid (umol/L, before treatment) | 506.28 ± 79.88 | 501.12 ± 95.49 | 0.824 |
VAS score (before treatment) | 8.38 ± 0.97 | 8.34 ± 0.97 | 0.876 |
The score for joint swelling (before treatment) | 5.93 ± 1.44 | 5.90 ± 1.63 | 0.941 |
The score for joint tenderness (before treatment) | 7.03 ± 1.84 | 6.93 ± 1.81 | 0.836 |
The score for joint mobility function (before treatment) | 2.45 ± 0.57 | 2.41 ± 0.50 | 0.777 |
The score for TCM syndrome (before treatment) | 19.69 ± 4.18 | 19.55 ± 3.81 | 0.894 |